Compare FRPH & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | VSTM |
|---|---|---|
| Founded | 1986 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 470.7M |
| IPO Year | N/A | 2012 |
| Metric | FRPH | VSTM |
|---|---|---|
| Price | $23.78 | $5.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 54.8K | ★ 1.6M |
| Earning Date | 03-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $33,049,999.00 | $13,379,000.00 |
| Revenue This Year | N/A | $208.54 |
| Revenue Next Year | N/A | $251.40 |
| P/E Ratio | $97.41 | ★ N/A |
| Revenue Growth | 5.21 | ★ 33.79 |
| 52 Week Low | $21.68 | $4.01 |
| 52 Week High | $31.99 | $11.25 |
| Indicator | FRPH | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 39.85 |
| Support Level | $23.33 | $5.80 |
| Resistance Level | $24.35 | $6.81 |
| Average True Range (ATR) | 0.50 | 0.40 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 51.09 | 13.60 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.